Sacituzumab Govitecan (Trodelvy)
Trop-2-directed antibody-drug conjugate for metastatic triple-negative and HR+/HER2- breast cancer after prior therapies.
What is Sacituzumab Govitecan?
What it targets
Trop-2, a protein expressed on the surface of triple-negative and HR-positive/HER2-negative breast cancer cells — the antibody binds here to deliver its chemotherapy payload directly to the tumor.
Who it may help
Patients with metastatic or unresectable locally advanced triple-negative breast cancer, or HR-positive/HER2-negative breast cancer, who have already had multiple prior systemic therapies.
Why testing matters
ER, PR, and HER2 receptor testing confirms your breast cancer subtype and which approved indication applies. Routine Trop-2 testing is not currently required for approved indications.
Which cancers can Sacituzumab Govitecan treat?
Sacituzumab govitecan is approved for specific breast cancer subtypes in advanced or metastatic settings. Eligibility depends on cancer subtype, prior treatment history, and regulatory approval in your country.
| Triple-Negative Breast Cancer (TNBC) | FDA-approved for adults with unresectable locally advanced or metastatic TNBC after two or more prior systemic therapies, including at least one for metastatic disease. EMA and China NMPA have also approved this indication. |
| HR-Positive / HER2-Negative Breast Cancer | FDA-approved for adults with unresectable locally advanced or metastatic HR+/HER2- breast cancer after endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. |
| Urothelial / Bladder Cancer (USA — withdrawn) | The US accelerated approval for metastatic urothelial cancer was voluntarily withdrawn by Gilead in consultation with the FDA in 2024. Patients should check current local approval and explore clinical trial options. |
| Other Trop-2-Expressing Tumours (investigational) | Being studied in clinical trials for lung, head and neck, gynecologic, and other solid tumours with Trop-2 expression. Trial use is not the same as routine approved treatment. |
Who may be eligible for Sacituzumab Govitecan?
Eligibility depends on cancer subtype, prior treatment history, organ function, and overall fitness for treatment. Your oncologist will review all of these before recommending this drug.
- Confirmed diagnosis of metastatic or unresectable locally advanced TNBC or HR+/HER2- breast cancer.
- For TNBC: at least two prior systemic therapies, including at least one for metastatic disease.
- For HR+/HER2- breast cancer: prior endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
- Adequate bone marrow function — sufficient neutrophil and platelet counts before starting treatment.
- Adequate liver and kidney function, assessed by blood tests before each cycle.
- Good enough general fitness (performance status) to tolerate IV infusion and monitor for infusion reactions.
- Not pregnant or breastfeeding — the drug can harm an unborn baby or infant.
- Drug is approved in your country for your specific cancer subtype, or access is available via a named-patient or trial pathway.
How does Sacituzumab Govitecan work?
- Antibody targets Trop-2
- Drug is internalised by cancer cells
- SN-38 inhibits topoisomerase I
- Bystander effect on nearby cancer cells
Tests needed before and during treatment
Baseline tests confirm eligibility, establish monitoring benchmarks, and ensure safe dosing. Tests are repeated regularly throughout treatment.
| Biopsy and histopathology | Confirms cancer type, subtype, and prior receptor testing (ER, PR, HER2). Required before treatment can be planned. |
| ER, PR, HER2 status | Confirms TNBC (ER-, PR-, HER2-) or HR+/HER2- subtype. Results must match the approved indication. |
| Complete Blood Count (CBC) | Checked before every cycle to assess neutrophil and platelet counts. Severe neutropenia can delay or reduce dosing. |
| Liver Function Tests | Assessed before and during treatment. Abnormal liver function may affect drug metabolism and require dose adjustment. |
| Kidney Function Tests | Baseline kidney function is assessed before treatment starts and monitored as needed. |
| Imaging (CT / PET-CT / MRI) | Baseline scans assess disease extent and provide reference for response monitoring. Repeated every few cycles. |
| Prior treatment review | Oncologist reviews all prior chemotherapy, endocrine therapy, CDK4/6 inhibitors, immunotherapy, and ADC use to confirm eligibility. |
| Pregnancy test | Required for women of childbearing potential before starting treatment. The drug is harmful to an unborn baby. |
How is Sacituzumab Govitecan given?
Sacituzumab govitecan is given by intravenous (IV) infusion in a cancer centre or infusion facility. It cannot be taken at home.
| Standard dose | 10 mg/kg body weight per infusion, given on day 1 and day 8 of a repeating 21-day cycle. |
| Route | Intravenous infusion administered by a trained oncology nurse in a cancer centre or infusion unit. |
| Infusion duration | First infusion takes approximately 3 hours. Subsequent infusions may be given over 1–2 hours if prior infusions were well tolerated. |
| Monitoring after infusion | Patients are monitored for at least 30 minutes after each infusion for infusion reactions, including allergic symptoms. |
| Pre-medications | Antihistamines and other pre-medications may be given before infusion to reduce the risk of infusion-related reactions. |
| Dose delays and reductions | Doses may be withheld or reduced if neutrophil counts are too low, if severe diarrhea occurs, or if other significant toxicities develop. |
| Duration of treatment | Treatment continues until the cancer progresses, side effects become unacceptable, or the oncologist decides a change is needed. There is no fixed number of cycles. |
| G-CSF support | G-CSF (granulocyte colony-stimulating factor) may be prescribed to help prevent or treat severe neutropenia in selected patients. |
Clinical evidence and benefits
Sacituzumab govitecan has been evaluated in major clinical trials in metastatic TNBC and pre-treated HR+/HER2- metastatic breast cancer, and has demonstrated meaningful improvement compared with standard chemotherapy options.
| ASCENT trial — metastatic TNBC | In the ASCENT trial, sacituzumab govitecan showed substantially longer progression-free survival and overall survival compared with physician's choice single-agent chemotherapy in previously treated metastatic TNBC. |
| TROPiCS-02 trial — HR+/HER2- breast cancer | In the TROPiCS-02 trial in heavily pre-treated HR+/HER2- metastatic breast cancer, it improved progression-free survival compared with physician's choice chemotherapy, with an overall survival benefit also observed. |
| Tumour shrinkage in selected patients | Meaningful objective tumour responses have been reported in metastatic TNBC and HR+/HER2- breast cancer, providing disease control in a group with limited standard options. |
| Treatment option after multiple prior therapies | Provides an active treatment option for patients who have already received multiple lines of treatment, including endocrine therapy, CDK4/6 inhibitors, chemotherapy, and immunotherapy. |
| Established data in TNBC — an aggressive subtype | TNBC has fewer targeted treatment options than other breast cancer subtypes. Sacituzumab govitecan is one of the few agents with a proven survival benefit in pre-treated metastatic TNBC. |
Individual responses vary. These represent published clinical trial data and may not apply to every patient. Your oncologist will advise on expected benefit based on your specific situation.
Side effects of Sacituzumab Govitecan
Sacituzumab govitecan carries two important black-box-level warnings: severe neutropenia and severe diarrhea. Most other side effects are manageable with supportive care, but patients need regular monitoring and should know when to contact their cancer team urgently.
| Neutropenia (low white blood cells) | Very common and one of the most serious risks. CBC must be checked before every cycle. Febrile neutropenia (fever with low counts) requires urgent hospital assessment. |
| Severe diarrhea | Can occur early in treatment. Anti-diarrheal treatment should be started promptly. Severe or persistent diarrhea requires dose delay or reduction and urgent oncology review. |
| Nausea | Common during and after infusion. Anti-nausea medications are usually prescribed to manage this. |
| Fatigue | Very common throughout treatment. Rest and activity pacing can help manage day-to-day energy levels. |
| Hair loss (alopecia) | Common. Hair typically begins to grow back after treatment ends. |
| Anaemia (low red blood cells) | Can cause tiredness and breathlessness. Blood counts are monitored regularly; transfusion may be needed in some cases. |
| Vomiting and decreased appetite | Common, particularly early in treatment. Anti-emetics and dietary support are usually recommended. |
| Constipation | Less common than diarrhea but reported. Hydration and dietary adjustments are usually effective. |
| Infusion-related reactions | Can include flushing, chills, fever, or allergic symptoms during infusion. Pre-medications and post-infusion monitoring reduce this risk. |
| Abdominal pain and colitis | Reported as serious adverse reactions in clinical studies. Seek oncology review if persistent or severe abdominal pain develops. |
| Pneumonia and infection risk | Neutropenia increases susceptibility to serious infections including pneumonia. Any fever or infection signs during treatment require urgent review. |
Contact your doctor immediately if you develop:
- Fever (temperature above 38°C / 100.4°F) — this may indicate febrile neutropenia, which is a medical emergency.
- Severe diarrhea — more than 4 episodes per day, bloody diarrhea, or diarrhea with dehydration.
- Signs of infection: chills, sweating, painful urination, cough, or redness at the IV site.
- Breathing difficulty, chest pain, or severe allergic reaction during or after infusion.
- Severe or persistent abdominal pain, or any signs of colitis.
Safety precautions and drug interactions
Tell your oncologist and pharmacist about all medicines, supplements, and herbal products before starting sacituzumab govitecan. Several interactions are clinically significant.
- UGT1A1 inhibitors (e.g. some antivirals and certain antibiotics) can increase SN-38 exposure and worsen toxicity — inform your oncologist of all current medications.
- UGT1A1 inducers can reduce SN-38 levels, potentially lowering effectiveness — avoid starting new medications without oncology review.
- Patients with UGT1A1*28 homozygous genotype may have reduced ability to clear SN-38, increasing toxicity risk — genetic testing may be relevant in some settings.
- Do not use during pregnancy — sacituzumab govitecan can cause fetal harm. Effective contraception is required during treatment and for a period after the last dose.
- Do not breastfeed during treatment or for a period after the last dose — potential risk to the infant.
- Avoid live vaccines during treatment — immunosuppression from neutropenia increases infection risk from live-attenuated vaccines.
- Tell your oncologist if you have existing liver disease, bowel conditions, chronic diarrhea, or active infection before starting treatment.
Sacituzumab Govitecan combination treatments
Sacituzumab govitecan is approved and most commonly used as a single agent in its approved breast cancer indications. Combination approaches are being explored in clinical trials.
| Sacituzumab govitecan + pembrolizumab | Being studied in combination with PD-1 checkpoint inhibitors in TNBC and other solid tumours — trial use only at this stage. |
| Sacituzumab govitecan + endocrine therapy | Being explored in HR+/HER2- breast cancer in combination with endocrine-based regimens in clinical trials. |
| After prior ADC therapy | Patients who have received T-DM1 or T-DXd may still be candidates — discuss with your specialist whether sequential ADC use is appropriate for your case. |
| Options if sacituzumab govitecan fails | Further ADCs, chemotherapy agents, targeted therapy, endocrine-based regimens, palliative radiotherapy, or clinical trial enrolment may be considered. |
If Sacituzumab Govitecan stops working
If the cancer progresses on sacituzumab govitecan, imaging and oncology review will guide the next steps. Understanding how resistance develops helps identify the best next option.
| Trop-2 expression changes | Downregulation or loss of Trop-2 on cancer cells may reduce the drug's ability to bind and deliver its payload. Re-biopsy or liquid biopsy may be considered. |
| SN-38 resistance mechanisms | Upregulation of drug efflux pumps or alterations in topoisomerase I may reduce SN-38 activity. This is an area of active research. |
| Next-line options after TNBC progression | Options may include other chemotherapy agents, PARP inhibitors if BRCA-mutated, immunotherapy, or clinical trial enrolment depending on prior treatment history. |
| Next-line options after HR+/HER2- progression | Options may include further chemotherapy, HER2-low targeting agents if eligible, PARP inhibitors in BRCA carriers, or clinical trials. |
| Second opinion when progression occurs | A specialist second opinion is often valuable when sacituzumab govitecan stops working, especially for patients with TNBC or heavily pre-treated HR+/HER2- disease. |
Cost of Sacituzumab Govitecan by country
Sacituzumab govitecan is an antibody-drug conjugate with significant per-cycle costs. Total treatment cost includes drug cost, infusion fees, blood monitoring, G-CSF support, and management of complications.
| India | Not yet locally manufactured. Access in India typically relies on import pathways, which significantly increases cost. Hospital agreements and import policies vary — contact CancerFax for current access options. |
| USA | Branded Trodelvy costs are high per cycle. Gilead offers a patient assistance programme for eligible uninsured or underinsured patients. Private insurance and Medicare coverage are available for approved indications. |
| UK / Europe | NICE-approved and available via the NHS in England for specific TNBC and HR+/HER2- indications. EMA-approved across Europe; national reimbursement varies by country. |
| China | NMPA-approved for metastatic TNBC after two prior therapies. Approved through Everest Medicines. Availability in hospitals and reimbursement status should be verified locally. |
| Other countries | Approved in multiple countries globally. Access and cost vary by regulatory status, insurance coverage, and hospital agreements. CancerFax can help identify options in your country. |
Availability of Sacituzumab Govitecan globally
Sacituzumab govitecan has broad global regulatory approval. Access depends on local approval status, hospital supply, and insurance or reimbursement pathways in each country.
USA
FDA-approved for metastatic TNBC and HR+/HER2- breast cancer. Widely available through oncology centres and infusion facilities. Patient assistance programme available through Gilead for eligible patients.
Europe (EMA)
EMA-approved for the same breast cancer indications. NHS England has approved it for selected TNBC and HR+/HER2- patients. National reimbursement varies across EU member states.
China
NMPA-approved for metastatic TNBC after two or more prior systemic therapies, commercialised through Everest Medicines. Availability and reimbursement at individual hospitals should be verified.
India
Not yet domestically approved or manufactured as of 2026. Access may be possible through named-patient import pathways at select oncology hospitals. Cost and availability vary — contact CancerFax for current access options.
Singapore / Australia
Regulatory approvals in force in Singapore and Australia for approved breast cancer indications. Available at major oncology centres.
Sacituzumab Govitecan in clinical trials
Sacituzumab govitecan is being studied in additional cancer types and in new combinations, building on its established use in breast cancer. Patients who have exhausted standard options may wish to explore active trials.
| Lung cancer | Trials ongoing in non-small cell lung cancer and other Trop-2-expressing thoracic tumours where standard ADCs are not yet available. |
| Head and neck cancers | Being studied in recurrent or metastatic head and neck squamous cell carcinoma where Trop-2 is frequently expressed. |
| Gynecologic cancers | Trials in endometrial, cervical, and other gynecologic cancers with Trop-2 expression are ongoing across multiple international sites. |
| Combinations with immunotherapy | Trials combining sacituzumab govitecan with checkpoint inhibitors (PD-1/PD-L1 antibodies) are ongoing in TNBC and other solid tumours. |
| Earlier lines of treatment | Trials exploring use in earlier metastatic or even neoadjuvant settings in TNBC — results from these studies will influence future treatment guidelines. |
Your treatment journey with Sacituzumab Govitecan
Diagnosis and subtype confirmation
Prior treatment review and eligibility check
Baseline tests and imaging
Infusion planning and pre-medications
Cycle 1 and early monitoring
Response assessment scans
Managing ongoing toxicity
Progression or treatment change decision
Questions to ask your oncologist about Sacituzumab Govitecan
- Is my cancer subtype eligible — TNBC or HR+/HER2-negative?
- Have I received enough prior treatments to qualify?
- Is sacituzumab govitecan approved in my country for my diagnosis?
- What should I do if I develop fever or diarrhea?
- Will I need G-CSF injections to support my white blood cells?
- How often will I need blood tests and scans?
- What are my options if this drug stops working?
- What is the total expected cost per cycle and per treatment course?
How CancerFax supports Sacituzumab Govitecan patients
CancerFax helps patients with TNBC and HR+/HER2- breast cancer understand whether sacituzumab govitecan is appropriate, and navigate access, cost, and specialist connections across India and internationally.
| Report review | Upload your pathology, receptor status, prior treatment summary, and CBC reports — our oncology team will review and explain the implications for sacituzumab govitecan eligibility. |
| Specialist connection | We connect patients with breast oncologists who specialise in TNBC, HR+/HER2- disease, and antibody-drug conjugates in India, China, Singapore, UAE, and other countries. |
| Access and import guidance | For patients in India and countries where Trodelvy is not locally approved, we help identify import pathways, hospital agreements, and named-patient access routes. |
| Cost navigation | We help patients understand the full cost of a treatment course and identify Gilead patient assistance programmes, insurance pathways, and lower-cost access options. |
| Second opinion coordination | If your oncologist is uncertain about eligibility, or if the drug has stopped working, CancerFax arranges a specialist breast oncology second opinion with ADC expertise. |
| Clinical trial matching | For patients in India, China, or other countries, we identify open clinical trials of sacituzumab govitecan or next-generation Trop-2 ADCs and help assess eligibility. |
Frequently asked questions about Sacituzumab Govitecan
Common questions from patients and caregivers about Trodelvy
Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate — it combines an antibody that targets the Trop-2 protein on cancer cells with a chemotherapy payload called SN-38. Unlike standard chemotherapy that circulates through the whole body, it is designed to deliver SN-38 more directly to Trop-2-expressing cancer cells. This targeted delivery approach is why it is used in specific breast cancer subtypes rather than as a general chemotherapy.
Sacituzumab govitecan is FDA-approved in the USA and EMA-approved in Europe for metastatic triple-negative breast cancer after two or more prior therapies. China's NMPA has also approved it for metastatic TNBC. Availability in India and other countries depends on the local regulatory status and hospital import pathways. Your oncologist or CancerFax can advise on access in your specific country.
For the currently approved indications in triple-negative breast cancer and HR-positive/HER2-negative breast cancer, Trop-2 testing is not routinely required before starting treatment, because Trop-2 is expressed broadly in these subtypes. However, research is ongoing to determine whether Trop-2 expression level predicts benefit. Your oncologist will review your cancer type, prior treatments, and test results to determine eligibility.
The two most important safety warnings for sacituzumab govitecan are severe neutropenia (dangerously low white blood cells) and severe diarrhea, both of which can be life-threatening if untreated. You should contact your oncology team immediately if you develop fever, chills, severe diarrhea, signs of infection, or difficulty breathing. Regular blood count monitoring is required throughout treatment to catch neutropenia early.
Treatment is typically continued as long as the cancer is responding and side effects are manageable. It is given on day 1 and day 8 of a repeating 21-day cycle, with reassessment scans performed periodically. Your oncologist will advise on stopping or switching based on scan results, blood counts, and your overall tolerance of treatment. There is no fixed number of cycles — the duration depends on your individual response.
In the United States, the accelerated approval for metastatic urothelial (bladder) cancer was voluntarily withdrawn by Gilead in consultation with the FDA in 2024. This means it is no longer a standard approved option for bladder cancer in the USA. Patients with urothelial cancer should discuss current approved options and clinical trial availability with their oncologist, as the situation may differ in other countries.
Prior ADC use does not automatically disqualify you, but your oncologist will carefully review your treatment history, organ function, and prior toxicities before recommending sacituzumab govitecan. In HR-positive/HER2-negative breast cancer, patients who have previously received T-DM1 or T-DXd may still be candidates depending on clinical context. This decision should always be made by a specialist oncologist familiar with your full treatment history.
Sacituzumab govitecan is a newer antibody-drug conjugate and carries a significant cost per cycle, especially when infusion fees, blood tests, G-CSF support, and anti-diarrheal medications are included. Gilead offers patient assistance programs in the USA for eligible patients. In India, availability and cost depend on import pathways and hospital agreements. CancerFax can help you explore cost navigation, insurance support, and access pathways in your country.